Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. The webcast, led by President and CEO Panna Sharma and members of the management team, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s RADR® and Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma’s website after the event.
The announcement comes as Lantern Pharma continues to integrate AI across its drug development pipeline. The company’s proprietary RADR® platform uses machine learning to analyze cancer genomics and drug response data, aiming to improve the efficiency and success rates of oncology drug development. This technology underpins several of Lantern’s clinical programs, including LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
In addition to its clinical pipeline, Lantern has made a strategic move to commercialize its AI capabilities. Zeta.ai, the company’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This marks a new revenue stream for the company, potentially diversifying its income beyond traditional biotech funding. By offering its AI tools to external researchers, Lantern could accelerate drug discovery across the industry while generating recurring revenue.
The webcast will likely provide insights into the adoption of Zeta.ai and how it is being used by external partners. Investors will also be looking for updates on Lantern’s clinical trials, particularly any data readouts or patient enrollment milestones. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas, reflecting its global footprint.
The implications of this announcement extend beyond Lantern’s own pipeline. The commercial availability of Zeta.ai highlights a growing trend of AI-first biotech companies monetizing their platforms. For industry leaders, this could signal new opportunities for collaboration and data sharing, potentially lowering the cost and time of drug development. For investors, the success of Zeta.ai could be a key metric for Lantern’s long-term valuation, as it offers a scalable business model separate from clinical success.
Lantern Pharma’s focus on AI-driven precision oncology is part of a broader shift in the pharmaceutical industry toward personalized medicine. The company’s ability to leverage large datasets and machine learning to identify patient subgroups most likely to respond to therapies could improve clinical trial outcomes and reduce failure rates. As the company prepares to report its Q2 results, stakeholders will be watching for evidence that these AI tools are translating into tangible progress.
For more details on the announcement, the full press release is available at https://ibn.fm/l80kv. Additional information about Lantern Pharma can be found in its newsroom at https://ibn.fm/LTRN.
